- Author: Hoda Z Abdel-Hamid, MD; Chief Editor: Amy Kao, MD more...
Cerebral palsy is the leading cause of childhood disability affecting function and development. The incidence of the condition has not changed in more than 4 decades, despite significant advances in the medical care of neonates.
The magnetic resonance image (MRI) below illustrates the findings in a 16-month-old boy with cerebral palsy.
Signs and symptoms
Signs of cerebral palsy include the following:
History of gross motor developmental delay in the first year of life
Abnormal muscle tone: The most frequently observed symptom; the child may present as either hypotonic or, more commonly, hypertonic, with either decreased or increased resistance to passive movements, respectively; children with cerebral palsy may have an early period of hypotonia followed by hypertonia. A combination of axial hypotonia and peripheral hyprtonia is indicative of a central process.
Definite hand preference before age 1 year: A red flag for possible hemiplegia
Asymmetrical crawling or failure to crawl
Growth disturbance: Especially failure to thrive
Increased reflexes: Indicating the presence of an upper motor neuron lesion; this condition may also present as the persistence of primitive reflexes
Underdevelopment or absence of postural or protective reflexes
The patient’s overall gait pattern should be observed, and each joint in the lower and upper extremity should be assessed for signs of cerebral palsy, including the following:
Hip: Excessive flexion, adduction, and femoral anteversion make up the predominant motor pattern; scissoring of the legs is common in spastic cerebral palsy
Knee: Flexion and extension with valgus or varus stress occur
Foot: Equinus, or toe walking, and varus or valgus of the hindfoot is common in cerebral palsy
See Clinical Presentation for more detail.
The diagnosis of cerebral palsy is generally made based on the clinical picture. There are no definitive laboratory studies for diagnosing the condition, only studies, including the following, to rule out other symptom causes:
Thyroid function studies: Abnormal thyroid function may be related to abnormalities in muscle tone or deep tendon reflexes or to movement disorders
Lactate and pyruvate levels: Abnormalities may indicate an abnormality of energy metabolism (ie, mitochondrial cytopathy)
Ammonia levels: Elevated ammonia levels may indicate liver dysfunction or urea cycle defect
Organic and amino acids: Serum quantitative amino acid and urine quantitative organic acid values may reveal inherited metabolic disorders
Chromosomal analysis: Chromosomal analysis, including karyotype analysis and specific DNA testing, may be indicated to rule out a genetic syndrome, if dysmorphic features or abnormalities of various organ systems are present
Cerebrospinal protein: levels may assist in determining asphyxia in the neonatal period; protein levels can be elevated, as can the lactate-to-pyruvate ratio
Cranial imaging studies to help evaluate brain damage and identify persons who are at risk for cerebral palsy include the following:
Cranial ultrasonography: Can be performed in the early neonatal period to delineate clear-cut structural abnormalities and show evidence of hemorrhage or hypoxic-ischemic injury
Computed tomography scanning of the brain: In infants, helps to identify congenital malformations, intracranial hemorrhage, and periventricular leukomalacia or early craniosynostosis.
Magnetic resonance imaging of the brain: The diagnostic neuroimaging study of choice because this modality defines cortical and white matter structures and abnormalities more clearly than does any other method; MRI also allows for the determination of whether appropriate myelination is present for a given age
Additional studies in cerebral palsy can include the following:
Electroencephalography: Important in the diagnosis of seizure disorders
Electromyography and nerve conduction studies: Helpful when a muscle or nerve disorder is suspected
See Workup for more detail.
Management of abnormal movements
Numerous medications, including the following, may relieve the movement difficulties associated with cerebral palsy:
Botulinum toxin with or without casting: Botulinum toxin (Botox) type A may reduce spasticity for 3-6 months and should be considered for children with cerebral palsy with spasticity. [1, 2, 3, 4, 5]
Phenol intramuscular neurolysis: This agent can be used for some large muscles or when several muscles are treated, but phenol therapy is permenant.
Antiparkinsonian, anticonvulsant, antidopaminergic, and antidepressant agents: Although antiparkinsonian drugs (eg, anticholinergic and dopaminergic drugs) and antispasticity agents (eg, baclofen) have primarily been used in the management of dystonia, anticonvulsants, antidopaminergic drugs, and antidepressants have also been tried
Surgical treatments used in patients with cerebral palsy include the following:
Intrathecal baclofen pump insertion: To treat spasticity and/or dystonia 
Selective dorsal rhizotomy: To treat velocity-dependent spasticity [7, 8]
Stereotactic basal ganglia: May improve rigidity, choreoathetosis, and tremor
Orthopedic surgical intervention: To treat scoliosis, joint contractures or dislocation
See Treatment and Medication for more detail.
The term cerebral palsy (CP) was originally coined more than a century ago and loosely translates as "brain paralysis." However, a precise definition has remained elusive because cerebral palsy is not a single diagnosis but an "umbrella" term describing nonprogressive brain lesions involving motor or postural abnormalities that are noted during early development. Cerebral palsy has been described as follows :
"A group of disorders of the development of movement and posture causing activity limitations that are attributed to non-progressive disturbances that occurred in the developing fetal or infant brain. The motor disorders of cerebral palsy are often accompanied by disturbances of sensation, cognition, communication, perception, and/or behavior and/or a seizure disorder."
Cerebral palsy is the leading cause of childhood disability affecting function and development. The brain lesions of cerebral palsy occur from the fetal or neonatal period to up to age 3 years. However, although insults to the brain after age 3 years through adulthood may manifest clinically as similar or identical to cerebral palsy, by definition, these lesions are not cerebral palsy. In addition, despite the fact that the lesion to the developing brain occurs before age 3 years, the diagnosis of cerebral palsy may not be made until after that time. Some authorities advocate not making a definitive diagnosis in selected cases until age 5 years or later. This approach allows the clinical picture to be clear and potentially allows exclusion of progressive diseases.[11, 12] In addition, some children have been diagnosed with cerebral palsy at an early age, only to have the symptoms resolve later.
The magnetic resonance image (MRI) below illustrates the findings in a 1-year-old former preterm boy with cerebral palsy.
Approximately 30-50% of patients with cerebral palsy have mental retardation, depending on the type.[14, 15] However, because of oromotor, fine motor, and gross motor difficulties, communication in these patients may be impaired and expression of intellectual capacity may be limited. However, if cerebral palsy is approached in a multidisciplinary manner, with physical, occupational, and nutritional therapy to maximize rehabilitative efforts, patients can be more fully integrated academically and socially.
Approximately 15-60% of children with cerebral palsy have epilepsy, and epilepsy is more frequent in patients with spastic quadriplegia or mental retardation.
See also the following:
Rehabilitation and Cerebral Palsy
Epilepsy and Seizures
Cerebral Venous Thrombosis
Periventricular Hemorrhage-Intraventricular Hemorrhage
Pediatric Periventricular Leukomalacia
Cerebral palsy is classified according to resting tone and what limbs are involved (called topographic predominance). Spastic cerebral palsy, due to cortex/pyramidal tract lesions, is the most common type and accounts for approximately 80% of cases ; this type of cerebral palsy is characterized by spasticity (velocity-dependent increase in tone), hyperreflexia, clonus, and an upgoing Babinski reflex.
Extrapyramidal or dyskinetic cerebral palsy comprises 10-15% of this disorder and is characterized more by abnormal involuntary movements. Ataxic cerebral palsy comprises less than 5% of cerebral palsy.
Many patients have characteristics of both spastic and extrapyramidal cerebral palsy. The typical types of cerebral palsy are as follows:
Spastic hemiplegia (20-30%) – Cerebral palsy predominantly affecting 1 side of the body, including an arm and a leg, with involvement of upper extremity spasticity more than lower extremity spasticity (eg, right side involved with right arm more than right leg). If both arms are more involved than the legs, the condition can be classified as a double hemiplegia.
Spastic diplegia (30-40%) – Cerebral palsy affecting bilateral lower extremities more than upper extremities; in some cases, the lower extremities are solely involved
Spastic quadriplegia (10-15%) – Cerebral palsy affecting all 4 extremities and the trunk (full body)
Dyskinetic cerebral palsy (athetoid, choreoathetoid, and dystonic) – Cerebral palsy with extrapyramidal signs characterized by abnormal movements; hypertonicity is often associated
Mixed cerebral palsy – Cerebral palsy with no single specific tonal quality predominating; typically characterized by a mixture of spastic and dyskinetic components
Hypotonic cerebral palsy – Cerebral palsy with truncal and extremity hypotonia with hyperreflexia and persistent primitive reflexes; thought to be rare
Monoplegia - Rare; involvement is noted in 1 limb, either an arm or a leg. If a patient has monoplegia, an effort should be made to rule out causes other than cerebral palsy.
Functional classification systems generally divide patients into mild, moderate, and severe types (depending on functional limitations). Alternatively, patients may be categorized more comprehensively by their abilities and limitations, as was proposed by the World Health Organization in 2001. See International Classification of Functioning, Disability and Health (ICF).
Cerebral palsy is generally considered a static encephalopathy (ie, nonprogressive in nature). However, the clinical presentation of this condition changes as children and their developing nervous systems mature.
Advances in neonatal neurology
Advances in neonatal neurology continue to focus on potentially modifiable factors during the neonatal period that contribute to the development of cerebral palsy. In recent years, several studies have shown that antenatal magnesium sulfate given to mothers at risk for preterm delivery is associated with a significant reduction in the risk of cerebral palsy.[16, 17, 18] Many other studies focus on the role of excitable amino acids and their role in neurologic injury. The hope is that more can be done in the neonatal period to prevent the permanent neurologic deficit resulting in cerebral palsy.
In summary, no set rules exist as to where or when the brain injury can occur, and injury may occur at more than one stage of fetal brain development. Additionally, causes are multiple and potentially multifactorial, including vascular insufficiency, infection, maternal factors, or underlying genetic abnormalities. Regardless of the etiology, however, the underlying brain anomaly in cerebral palsy is static, although the motor impairment and functional consequences may vary over time. By definition, cases associated with underlying disorders of a progressive or degenerative nature are excluded when diagnosing cerebral palsy.
Cerebral palsy is restricted to lesions of the brain only; diseases specific to the peripheral nerves of the spinal cord (eg, spinal muscular atrophy, myelomeningocele) or to the muscles (eg, muscular dystrophies), although causing early motor abnormalities, are not considered cerebral palsy.
Major events in human brain development and their peak times of occurrence include the following :
Primary neurulation – Weeks 3-4 of gestation
Prosencephalic development – Months 2-3 of gestation
Neuronal proliferation – Months 3-4 of gestation
Neuronal migration – Months 3-5 of gestation
Organization – Month 5 of gestation to years postnatal
Myelination – Birth to years postnatal
Cohort studies have shown an increased risk in children born slightly preterm (37-38 weeks) or postterm (42 weeks) compared with children born at 40 weeks.
Brain injury or abnormal brain development
Given the complexity of prenatal and neonatal brain development, injury or abnormal development may occur at any time, resulting in the varied clinical presentations of cerebral palsy (whether due to a genetic abnormality, toxic or infectious etiology, or vascular insufficiency). For example, cerebral injury before the 20th week of gestation can result in a neuronal migration deficit; injury between the 26th and 34th weeks can result in periventricular leukomalacia (foci of coagulative necrosis in the white matter adjacent to the lateral ventricles); injury between the 34th and 40th weeks can result in focal or multifocal cerebral injury.
Brain injury due to vascular insufficiency depends on various factors at the time of injury, including the vascular distribution to the brain, the efficiency of cerebral blood flow and regulation of blood flow, and the biochemical response of brain tissue to decreased oxygenation.
Prematurity and cerebral vasculature
The physical stress on premature infants and the immaturity of the brain and cerebral vasculature likely explain why prematurity is a significant risk factor for cerebral palsy. Before term, the distribution of fetal circulation to the brain results in the tendency for hypoperfusion to the periventricular white matter. Hypoperfusion can result in germinal matrix hemorrhages or periventricular leukomalacia. Between weeks 26 and 34 of gestation, the periventricular white matter areas near the lateral ventricles are most susceptible to injury. Because these areas carry fibers responsible for the motor control and muscle tone of the legs, injury can result in spastic diplegia (ie, predominant spasticity and weakness of the legs, with or without arm involvement of a lesser degree).
When larger lesions extend past the area of descending fibers from the motor cortex to involve the centrum semiovale and corona radiata, both the lower and upper extremities may be involved. Periventricular leukomalacia is generally symmetric and thought to be due to ischemic white matter injury in premature infants. Asymmetric injury to the periventricular white matter can result in one side of the body being more affected than the other. The result mimics a spastic hemiplegia but is best characterized as an asymmetric spastic diplegia. The germinal matrix capillaries in the periventricular region are particularly vulnerable to hypoxic-ischemic injury because of their location at a vascular border zone between the end zones of the striate and thalamic arteries. In addition, because they are brain capillaries, they have a high requirement for oxidative metabolism.
Periventricular hemorrhage-intraventricular hemorrhage
Many authorities grade the severity of periventricular hemorrhage-intraventricular hemorrhage using a classification system originally described by Papile et al in 1978 (see Periventricular Hemorrhage-Intraventricular Hemorrhage), as follows :
Grade I – Subependymal and/or germinal matrix hemorrhage
Grade II – Subependymal hemorrhage with extension into the lateral ventricles without ventricular enlargement
Grade III – Subependymal hemorrhage with extension into the lateral ventricles with ventricular enlargement
Grade IV – A germinal matrix hemorrhage that dissects and extends into the adjacent brain parenchyma, irrespective of the presence or absence of intraventricular hemorrhage, is also referred to as an intraparenchymal hemorrhage when found elsewhere in the parenchyma. Hemorrhage extending into the periventricular white matter in association with an ipsilateral germinal matrix hemorrhage/intraventricular hemorrhage is termed a periventricular hemorrhagic venous infarction.
Term cerebral vascular and hypoperfusion injuries
At term, when circulation to the brain most resembles adult cerebral circulation, vascular injuries at this time tend to occur most often in the distribution of the middle cerebral artery, resulting in a spastic hemiplegic cerebral palsy. However, the term brain is also susceptible to hypoperfusion, which mostly targets watershed areas of the cortex (eg, end zones of the major cerebral arteries), resulting in spastic quadriplegic cerebral palsy. The basal ganglia also can be affected, resulting in extrapyramidal or dyskinetic cerebral palsy.
The clinical presentation of cerebral palsy may result from an underlying structural abnormality of the brain; early prenatal, perinatal, or postnatal injury due to vascular insufficiency; toxins or infections; or the pathophysiologic risks of prematurity. These may include preterm birth, multiple gestation, intrauterine growth restriction, male sex, low Apgar scores, intrauterine infections, maternal thyroid abnormalities, prenatal strokes, birth asphyxia, maternal methyl mercury exposure, and maternal iodine deficiency.[12, 13, 22, 23] .
Evidence suggests that prenatal factors result in 70-80% of cases of cerebral palsy. In most cases, the exact cause is unknown but is most likely multifactorial.
Interpretation of the literature is limited by the lack of strict definitions in studies attempting to define a pathogenesis of cerebral palsy and the relatively small size of certain studies. An increasing amount of literature suggests a link between various prenatal, perinatal, and postnatal factors and this disorder. Epidemiologic studies suggest that prenatal factors play a predominant role in the etiology of cerebral palsy.
A Norwegian study involving children with cerebral palsy diagnosed before 5 years of age suggested that a low Apgar score at 5 minutes is associated with this order in all birth weights. The prevalence of cerebral palsy was highest in children with a low birth weight; however, the odds ratio of this order being associated with a low Apgar score (< 4) was highest in normal weight children. Nonetheless, most children with cerebral palsy had Apgar scores higher than 4 at 5 minutes.
Although preterm delivery is a well-established risk factor for cerebral palsy, a recent study suggests that postterm pregnancy at 42 weeks or later has been associated with an increased risk of this condition.
Maternal, prenatal, gestational risk factors
The following maternal and prenatal risk factors statistically correlate with cerebral palsy:
Long menstrual cycle
Previous pregnancy loss
Previous loss of newborn
Maternal mental retardation
Maternal thyroid disorder, especially iodine deficiency
Maternal seizure disorder
History of delivering a child weighing less than 2000 g
History of delivering a child with a motor deficit, mental retardation, or a sensory deficit
The following factors during pregnancy also correlate statistically with cerebral palsy:
Treatment of the mother with thyroid hormone, estrogen or progesterone
Maternal seizure disorder
Maternal severe proteinuria or high blood pressure
Maternal methyl mercury exposure
Congenital malformations in the fetus
Male sex of fetus
Bleeding in third trimester
Intrauterine growth retardation
The apparent overrepresentation of cerebral palsy in multiple gestation pregnancies may relate more to the presence of prematurity or intrauterine growth retardation. Multiple gestations may not be an added risk for this disorder. The exception is when one twin dies; the surviving twin has a higher chance than a singleton of developing cerebral palsy.
Perinatal risk factors
The following perinatal factors are associated with an increased risk of cerebral palsy:
Nonvertex and face presentation of the fetus
In 10% or less of cerebral palsy cases, birth asphyxia can be determined as the definitive cause. Even when birth asphyxia is thought to be associated clearly with cerebral palsy, abnormal prenatal factors (eg, intrauterine growth retardation, congenital brain malformations) may have contributed to perinatal fetal distress. Cases of cerebral palsy attributed to birth asphyxia must document clear evidence of acidosis, moderate to severe neonatal encephalopathy, restriction to spastic quadriplegia, dyskinetic or mixed types of cerebral palsy, and exclusion of other etiologies. Additionally, an intrapartum event must be suggested by a sentinel event, fetal heart rate changes, Apgar score less than 4 at 5 minutes, organ system damage related to tissue hypoxia, and early imaging abnormalities.
Although Apgar scores provide a method for documenting cardiopulmonary and neuromotor status in the minutes following birth, low scores alone cannot be used as an indicator of birth asphyxia. Such scores may reflect circumstances unrelated to birth asphyxia, such as infections and other preexisting prenatal conditions.
Postnatal risk factors
The following postnatal factors may contribute to cerebral palsy:
Infections (eg, meningitis, encephalitis)
Intracranial hemorrhage (eg, due to prematurity, vascular malformations, or trauma)
Periventricular leukomalacia (in premature infants)
Hypoxia-ischemia (eg, from meconium aspiration)
Persistent fetal circulation or persistent pulmonary hypertension of the newborn
Possible causes of cerebral palsy by type are discussed below.
Of all cases of cerebral palsy, 70-90% are congenital and 10-30% are acquired (eg, vascular, inflammatory, traumatic). In unilateral lesions of the brain, the vascular territory most commonly affected is the middle cerebral artery; the left side is involved twice as commonly as the right. Other structural brain abnormalities include hemi-brain atrophy and posthemorrhagic porencephaly. In premature infants, this may result from asymmetric periventricular leukomalacia.
In premature infants, spastic diplegia may result from parenchymal-intraventricular hemorrhage or periventricular leukomalacia. In term infants, no risk factors may be identifiable, or the etiology might be multifactorial.
Approximately 50% of spastic quadriplegic cerebral palsy cases are prenatal, 30% are perinatal, and 20% are postnatal in origin. This type is associated with cavities that communicate with the lateral ventricles, multiple cystic lesions in the white matter, diffuse cortical atrophy, and hydrocephalus.
The patient often has a history of a difficult delivery with evidence of perinatal asphyxia. Preterm infants may have periventricular leukomalacia. Full-term infants may have structural brain abnormalities or cerebral hypoperfusion in a watershed (ie, major cerebral artery end zone) distribution.
Dyskinetic (extrapyramidal) cerebral is associated with several unique etiologies. Historically, kernicterus, or acute neonatal bilirubin encephalopathy, was a major cause. With improvement in early management of hyperbilirubinemia, the vast majority cases of dyskinetic cerebral palsy are currently associated with presumed hypoxic ischemic injury rather than with hyperbilirubinemia. In the absence of hypoxia, hyperbilirubinemia, or prematurity, the possibility of a metabolic or neurodegenerative disorder as a basis for this presentation must be considered.
Thus, dyskinetic cerebral palsy may be associated with hyperbilirubinemia in term infants or with prematurity without prominent hyperbilirubinemia. Hypoxia affecting the basal ganglia and thalamus may affect term infants more than preterm infants.
The incidence of cerebral palsy has not changed in more than 4 decades, despite significant advances in the medical care of neonates.
In developed countries, the overall estimated prevalence of cerebral palsy is 2-2.5 cases per 1000 live births. The prevalence of this disorder among preterm and very preterm infants is substantially higher.[27, 28] In the developing world, the prevalence of cerebral palsy is not well established but estimates are 1.5-5.6 cases per 1000 live births. These figures may represent an underestimation because of a paucity of data, the lack of healthcare access, an overrepresentation of severe cases, and inconsistent diagnostic criteria.
With relation to age, the insult that gives rise to cerebral palsy occurs during immature brain development. According to most references, this initiating event can take place anytime between prenatal development and age 3 years. However, children are usually not diagnosed until after age 1 year, with the condition becoming identifiable as children fail to meet developmental milestones. Often, children who are older and are diagnosed as having cerebral palsy—as a result of having presenting symptoms or problems that are similar to those of cerebral palsy—should instead be labeled with the etiology of their brain injury (ie, traumatic brain injury secondary to a motor vehicle accident, stroke, metabolic condition, etc.
With appropriate therapeutic services, patients may be able to fully integrate academically and socially.
The morbidity and mortality of cerebral palsy relate to the severity of this condition and concomitant medical complications, such as respiratory and gastrointestinal difficulties. In patients with quadriplegia, the likelihood of epilepsy, extrapyramidal abnormalities, and severe cognitive impairment is greater than in those with diplegia or hemiplegia.
Cognitive impairment occurs more frequently in persons with cerebral than in the general population. The overall rate of mental retardation in affected persons is thought to be 30-50%. Some form of learning disability (including mental retardation) has been estimated to occur in perhaps 75% of patients. However, standardized cognitive testing primarily evaluates verbal skills and may result in the underestimation of cognitive abilities in some individuals.
In some studies, 25% of patients with cerebral palsy are unable to walk. However, many patients with this disorder (particularly those with spastic diplegia and spastic hemiplegia types) can ambulate independently or with assistive equipment. Thus, approximately 25% of children with cerebral palsy have mild involvement with minimal or no functional limitation in ambulation, self-care, and other activities. Approximately half are moderately impaired to the extent that complete independence is unlikely but function is satisfactory. Only 25% are so severely disabled that they require extensive care and are nonambulatory.
A prospective study of children has suggested that being able to sit by age 2 years is a good predictive sign of eventual ambulation. The suppression of obligatory primitive reflex activity by age 18-24 months was a sensitive indicator for distinguishing children who ultimately walked from those who were not expected to walk. Children who did not sit by age 4 years did not ambulate.
In patients with spastic quadriplegia, a less favorable prognosis correlated with a longer delay in the resolution of extensor tone. At times, hypertonicity and spasticity may improve or resolve over time in patients with cerebral palsy. Spasticity in patients with spastic quadriplegia can be more resistant even with services and orthopedic and rehabilitative intervention.
Patients with severe forms of cerebral palsy may have a significantly reduced life span, although this continues to improve with improved health care and gastrostomy tubes. Patients with milder forms of this disorder have a life expectancy close to the general population, although it is still somewhat reduced.[31, 32, 33]
Cerebral palsy complications may affect multiple systems. For example, skin complications include decubitus ulcers and sores; orthopedic complications may include contractures, hip dislocation, and/or scoliosis.
Maintaining weight close to idea body weight is important for wheelchair-bound patients or those with ambulatory dysfunction. Nutrition consultation should be done early and periodically to ensure proper growth. Parents and medical professionals must keep on top of the potential nutritional difficulties in children with cerebral palsy. These patients are especially at risk of developing osteoporosis because of decreased weight bearing, so following their calcium intake is important.
Gastrointestinal and nutritional complications include the following:
Failure to thrive due to feeding and swallowing difficulties secondary to poor oromotor control; patients may require a gastrostomy tube (G-tube) or a jejunostomy tube (J-tube) to augment nutrition.
Obesity, less frequently than failure to thrive
Gastroesophageal reflux and associated aspiration pneumonia
Dental problems also include enamel dysgenesis, malocclusion, and gingival hyperplasia. Malocclusion is twice as prevalent as in the normal population. The increased incidence of dental problems is often secondary to the use of medications, especially drugs administered to premature infants and antiepileptic agents.
Respiratory complications include the following:
Increased risk of aspiration pneumonia because of oromotor dysfunction
Chronic lung disease/bronchopulmonary dysplasia
Neurologic complications include the following:
Hearing loss (particularly in patients who had acute bilirubin encephalopathy [kernicterus]; also seen in patients who were born prematurely or who were exposed to ototoxic drugs)
Visual-field abnormalities due to cortical injury
Epilepsy occurs in 15-60% of children with cerebral palsy and is more common in patients with spastic quadriplegia or mental retardation. When compared with controls, children with cerebral palsy have a higher incidence of epilepsy with onset within the first year of life and are more likely to have a history of neonatal seizures, status epilepticus, polytherapy, and treatment with second-line anticonvulsants. Factors associated with a seizure-free period of at least 1 year include normal intelligence, single seizure type, monotherapy, and spastic diplegia.
Visual acuity decreases in premature infants because of retinopathy of prematurity with hypervascularization and possible retinal detachment.
Cognitive/psychologic/behavioral complications include the following:
Mental retardation (30-50%), most commonly associated with spastic quadriplegia
Impact on academic performance and self-esteem
Increased prevalence of depression
Sensory integration difficulties
Increased prevalence of progressive development disorder or autism associated with concurrent diagnosis of cerebral palsy
Patients with cerebral palsy and their caregivers should be aware that oromotor dysfunction may require limitations in the texture of food and liquid, feeding only by gastrostomy or jejunostomy tube, supplemental feedings via gastrostomy or jejunostomy tube to increase energy intake, and aspiration precautions.
In addition, regular physical therapy and occupational therapy are crucial in these individuals. The goal should be to maximize the functional use of limbs and ambulation and to reduce the risk of contractures.
For patient education information, see Brain and Nervous System Center as well as Cerebral Palsy.
Simpson DM, Gracies JM, Graham HK, Miyasaki JM, Naumann M, Russman B, et al. Assessment: Botulinum neurotoxin for the treatment of spasticity (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2008 May 6. 70(19):1691-8. [Medline].
Scholtes VA, Dallmeijer AJ, Knol DL, Speth LA, Maathuis CG, Jongerius PH, et al. The combined effect of lower-limb multilevel botulinum toxin type a and comprehensive rehabilitation on mobility in children with cerebral palsy: a randomized clinical trial. Arch Phys Med Rehabil. 2006 Dec. 87(12):1551-8. [Medline].
Dai AI, Wasay M, Awan S. Botulinum toxin type A with oral baclofen versus oral tizanidine: a nonrandomized pilot comparison in patients with cerebral palsy and spastic equinus foot deformity. J Child Neurol. 2008 Dec. 23(12):1464-6. [Medline].
Yang EJ, Rha DW, Kim HW, Park ES. Comparison of botulinum toxin type A injection and soft-tissue surgery to treat hip subluxation in children with cerebral palsy. Arch Phys Med Rehabil. 2008 Nov. 89(11):2108-13. [Medline].
Pascual-Pascual SI, Pascual-Castroviejo I. Safety of botulinum toxin type A in children younger than 2 years. Eur J Paediatr Neurol. 2009 Nov. 13(6):511-5. [Medline].
Hoving MA, van Raak EP, Spincemaille GH, Palmans LJ, Becher JG, Vles JS. Efficacy of intrathecal baclofen therapy in children with intractable spastic cerebral palsy: a randomised controlled trial. Eur J Paediatr Neurol. 2009 May. 13(3):240-6. [Medline].
Trost JP, Schwartz MH, Krach LE, Dunn ME, Novacheck TF. Comprehensive short-term outcome assessment of selective dorsal rhizotomy. Dev Med Child Neurol. 2008 Oct. 50(10):765-71. [Medline].
Nordmark E, Josenby AL, Lagergren J, Andersson G, Strömblad LG, Westbom L. Long-term outcomes five years after selective dorsal rhizotomy. BMC Pediatr. 2008 Dec 14. 8:54. [Medline]. [Full Text].
Mutch L, Alberman E, Hagberg B, Kodama K, Perat MV. Cerebral palsy epidemiology: where are we now and where are we going?. Dev Med Child Neurol. 1992 Jun. 34(6):547-51. [Medline].
Bax M, Goldstein M, Rosenbaum P, Leviton A, Paneth N, Dan B, et al. Proposed definition and classification of cerebral palsy, April 2005. Dev Med Child Neurol. 2005 Aug. 47(8):571-6. [Medline].
Shevell MI, Bodensteiner JB. Cerebral palsy: defining the problem. Semin Pediatr Neurol. 2004 Mar. 11(1):2-4. [Medline].
Stanley F, Blair E, Alberman E. Cerebal Palsies: Epidemiology and Causal Pathways. London, United Kingdom: MacKeith Press; 2000.
Jacobsson B, Hagberg G. Antenatal risk factors for cerebral palsy. Best Pract Res Clin Obstet Gynaecol. 2004 Jun. 18(3):425-36. [Medline].
Odding E, Roebroeck ME, Stam HJ. The epidemiology of cerebral palsy: incidence, impairments and risk factors. Disabil Rehabil. 2006 Feb 28. 28(4):183-91. [Medline].
Russman BS, Ashwal S. Evaluation of the child with cerebral palsy. Semin Pediatr Neurol. 2004 Mar. 11(1):47-57. [Medline].
Doyle LW, Crowther CA, Middleton P, Marret S, Rouse D. Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Cochrane Database Syst Rev. 2009 Jan 21. CD004661. [Medline].
Rouse DJ, Hirtz DG, Thom E, Varner MW, Spong CY, Mercer BM, et al. A randomized, controlled trial of magnesium sulfate for the prevention of cerebral palsy. N Engl J Med. 2008 Aug 28. 359(9):895-905. [Medline]. [Full Text].
Conde-Agudelo A, Romero R. Antenatal magnesium sulfate for the prevention of cerebral palsy in preterm infants less than 34 weeks' gestation: a systematic review and metaanalysis. Am J Obstet Gynecol. 2009 Jun. 200(6):595-609. [Medline].
Volpe JJ. Neurology of the Newborn. 4th ed. Philadelphia, Pa: WB Saunders; 2001. 4.
Moster D, Wilcox AJ, Vollset SE, Markestad T, Lie RT. Cerebral palsy among term and postterm births. JAMA. 2010 Sep 1. 304(9):976-82. [Medline].
Papile LA, Burstein J, Burstein R, Koffler H. Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm. J Pediatr. 1978 Apr. 92(4):529-34. [Medline].
Nelson KB. Can we prevent cerebral palsy?. N Engl J Med. 2003 Oct 30. 349(18):1765-9. [Medline].
Lie KK, Grøholt EK, Eskild A. Association of cerebral palsy with Apgar score in low and normal birthweight infants: population based cohort study. BMJ. 2010 Oct 6. 341:c4990. [Medline]. [Full Text].
American College of Obstetricians and Gynecologists, American Academy of Pediatrics. Neonatal Encephalopathy and Cerebral Palsy: Defining the Pathogenesis and Pathophysiology. Washington, DC: American College of Obstetricians and Gynecologists; 2003. [Full Text].
Capute AJ, Accardo PJ, eds. Developmental Disabilities in infancy and Childhood. 2nd ed. Baltimore, Md: Brookes Publishing; 2001. Vol 2.:
Majnemer A, Mazer B. New directions in the outcome evaluation of children with cerebral palsy. Semin Pediatr Neurol. 2004 Mar. 11(1):11-7. [Medline].
Vincer MJ, Allen AC, Joseph KS, Stinson DA, Scott H, Wood E. Increasing prevalence of cerebral palsy among very preterm infants: a population-based study. Pediatrics. 2006 Dec. 118(6):e1621-6. [Medline].
Ancel PY, Livinec F, Larroque B, Marret S, Arnaud C, Pierrat V, et al. Cerebral palsy among very preterm children in relation to gestational age and neonatal ultrasound abnormalities: the EPIPAGE cohort study. Pediatrics. 2006 Mar. 117(3):828-35. [Medline].
Dolk H, Pattenden S, Johnson A. Cerebral palsy, low birthweight and socio-economic deprivation: inequalities in a major cause of childhood disability. Paediatr Perinat Epidemiol. 2001 Oct. 15(4):359-63. [Medline].
Strauss D, Shavelle R, Reynolds R, Rosenbloom L, Day S. Survival in cerebral palsy in the last 20 years: signs of improvement?. Dev Med Child Neurol. 2007 Feb. 49(2):86-92. [Medline].
Hemming K, Hutton JL, Colver A, Platt MJ. Regional variation in survival of people with cerebral palsy in the United Kingdom. Pediatrics. 2005 Dec. 116(6):1383-90. [Medline].
Hemming K, Hutton JL, Pharoah PO. Long-term survival for a cohort of adults with cerebral palsy. Dev Med Child Neurol. 2006 Feb. 48(2):90-5. [Medline].
Hutton JL, Pharoah PO. Life expectancy in severe cerebral palsy. Arch Dis Child. 2006 Mar. 91(3):254-8. [Medline]. [Full Text].
Verrall TC, Berenbaum S, Chad KE, Nanson JL, Zello GA. Children with Cerebral Palsy: Caregivers' Nutrition Knowledge, Attitudes and Beliefs. Can J Diet Pract Res. 2000 Autumn. 61(3):128-134. [Medline].
Bax M, Tydeman C, Flodmark O. Clinical and MRI correlates of cerebral palsy: the European Cerebral Palsy Study. JAMA. 2006 Oct 4. 296(13):1602-8. [Medline].
Woodward LJ, Anderson PJ, Austin NC, Howard K, Inder TE. Neonatal MRI to predict neurodevelopmental outcomes in preterm infants. N Engl J Med. 2006 Aug 17. 355(7):685-94. [Medline].
Wyatt K, Edwards V, Franck L, Britten N, Creanor S, Maddick A, et al. Cranial osteopathy for children with cerebral palsy: a randomised controlled trial. Arch Dis Child. 2011 Jun. 96(6):505-12. [Medline].
Delgado MR, Tilton A, Russman B, Benavides O, Bonikowski M, Carranza J, et al. AbobotulinumtoxinA for Equinus Foot Deformity in Cerebral Palsy: A Randomized Controlled Trial. Pediatrics. 2016 Feb. 137 (2):e20152830. [Medline].
Edwards P, Sakzewski L, Copeland L, Gascoigne-Pees L, McLennan K, Thorley M, et al. Safety of Botulinum Toxin Type A for Children With Nonambulatory Cerebral Palsy. Pediatrics. 2015 Nov. 136 (5):895-904. [Medline].
Blackmore AM, Boettcher-Hunt E, Jordan M, Chan MD. A systematic review of the effects of casting on equinus in children with cerebral palsy: an evidence report of the AACPDM. Dev Med Child Neurol. 2007 Oct. 49(10):781-90. [Medline].
Delgado MR, Hirtz D, Aisen M, et al. Practice parameter: pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology. 2010 Jan 26. 74(4):336-43. [Medline].
Muthusamy K, Recktenwall SM, Friesen RM, Zuk J, Gralla J, Miller NH, et al. Effectiveness of an anesthetic continuous-infusion device in children with cerebral palsy undergoing orthopaedic surgery. J Pediatr Orthop. 2010 Dec. 30(8):840-5. [Medline].
Perlman JM. Intrapartum hypoxic-ischemic cerebral injury and subsequent cerebral palsy: medicolegal issues. Pediatrics. 1997 Jun. 99(6):851-9. [Medline]. [Full Text].
Du RY, McGrath CP, Yiu CK, King NM. Oral health behaviors of preschool children with cerebral palsy: a case-control community-based study. Spec Care Dentist. 2014 Nov-Dec. 34 (6):298-302. [Medline].
Anderson P. FDA Clears Stimulation System for Foot Drop in Children. Medscape Medical News. Jan 25 2013. Available at http://www.medscape.com/viewarticle/778221. Accessed: February 5, 2013.
Dabney KW, Lipton GE, Miller F. Cerebral palsy. Curr Opin Pediatr. 1997 Feb. 9(1):81-8. [Medline].
Girard S, Kadhim H, Roy M, Lavoie K, Brochu ME, Larouche A, et al. Role of perinatal inflammation in cerebral palsy. Pediatr Neurol. 2009 Mar. 40(3):168-74. [Medline].
Jones MW, Morgan E, Shelton JE, Thorogood C. Cerebral palsy: introduction and diagnosis (part I). J Pediatr Health Care. 2007 May-Jun. 21(3):146-52. [Medline].
Mattern-Baxter K. Effects of partial body weight supported treadmill training on children with cerebral palsy. Pediatr Phys Ther. 2009 Spring. 21(1):12-22. [Medline].